Overview

Emodepside Phase II Trial for Treatment of Onchocerciasis

Status:
Recruiting
Trial end date:
2026-10-02
Target enrollment:
Participant gender:
Summary
The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.
Phase:
Phase 2
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborator:
Bayer
Treatments:
Emodepside
Ivermectin